ESTRO 35 2016 ______________________________________________________________________________________________________ efficacy and visual outcomes of a large series of patients with choroidal melanoma (CM) treated with RuBT, and compare the results to those of the preceding protocol in which RuBT was combined with transpupillary thermotherapy (Ru/TTT).
Conclusion:
Both protocols for eye-conserving treatment of patients with choroidal melanoma provided excellent rates of local tumour control and eye preservation, with the RuBT protocol confirmed to be best standard of care with 97% eye preservation and significantly longer preservation of visual acuity. Purpose or Objective: The standard primary treatment for soft tissue sarcoma (STS) is radical surgical resection, preceded or followed by radiotherapy. The purpose of this retrospective study was to assess the efficacy and safety of perioperative brachytherapy (BT) plus postoperative external beam radiation therapy (EBRT) +/-chemotherapy (CT).
Material and Methods:
The primary aim of the study was evaluating local control (LC) and overall survival (OS) in a large patients population of treated with combined modality therapy. Secondary objectives were to identify prognostic factors for local recurrence (LR). BT was delivered with Pulsed Dose Rate. Total dose was 20 Gy (0.80 Gy/pulse). EBRT was delivered with 3D-technique by using multiple beams technique. The prescribed dose was 46 Gy (2Gy/fraction). Neoadjuvant and adjuvant chemotherapy was prescribed to patients with potentially chemo-sensitive histological subtypes. Univariate analysis was performed with the log-rank test and multivariate analysis with Cox's proportional hazard model.
Results
: From 2000 to 2011, 107 patients (median age 54 years; range 13-85) with high grade primary or recurrent STS were treated with surgery, perioperative BT and adjuvant EBRT +/-CT. Five year LC and OS were 82.2% and 87.8%, respectively. A higher LC was recorded in patients treated for primary tumor, lower limbs, and negative margins STS.
Conclusion:
The combination of BT and EBRT was able to achieve high LC and OS rates. A particular risk factor recorded was the disease site. These results warrant further prospective studies to define the role of BT boost in adjuvant therapy of resected STS. Results: 33 patients(19 males) were identified with either primary cardiac(73%) or great vessel sarcomas; median age of 46.9 (range 13-83). Presenting symptoms included dyspnoea(55%), pain(21%), cough/haemoptysis(11%), heart failure(24%), emboli(18%) or pulmonary HTN(12%). Diagnosis was on biopsy(42%) or following resection(58%). Atrial tumours accounted for 58% of cases. Surgery was performed in 66%, with R0(12%),R1(24%) ,R2(24%), or unknown (6%) margins. High grade tumours were seen in 17(52%) cases. Commonest histological subtypes were angiosarcoma (32%), and spindle cell (17%). Localised disease was observed in 18 (55%) cases. Median follow-up was 379 days. Group A, Radiotherapy: 15 patients received RT (6 males), 10 had operable tumours. 8 patients also received CT. Median time to first treatment was 57.9 days. Patients received 60 Gy/30#(n = 4), 59.4 Gy/33#(n = 3), 58 Gy/30#(n = 1), 50.4 Gy/28#(n = 3), 45 Gy/25#(n = 1), 35 Gy/15#(n = 1), or 20 Gy/5#(n= 1). 85% reported toxicity (oesophagitis, cough or fatigue). 8 (53%) patients developed a local recurrence (LR) and 13 patients developed metastatic disease (DM). 2 were long term survivors. Median time to DM for right sided lesions was 116 days, left sided, 1226 days. Overall survival was 2.1 years (R side) and 3.4 years (L side). Median OS was 803 days. Goup B, Chemotherapy: 13 patients received CT(10 males), 7 had operable tumours. Median time to first treatment was 44 days. Regimens were mainly alkylating/anthracycline/taxane based. 3 patients stopped early (toxicity). 10 patients had LR(77%) and 10 patients developed DM. 2 were long term survivors. Median OS was 296 days. Group C, Surgery:
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________________________________________________________________________________ 5 patients, 1 died 3 days after diagnosis. 4 patients had surgery, 3 developed DM and 1 is a long-term survivor. Median OS was 68 days.
Conclusion:
These rare sarcomas have variable clinical presentations. Surgery is the central component for successful treatment but complete resection is not always possible. RT may reduce LR (reduced from 77%, group B,to 53%, group A) and chemotherapy is offered if high risk (inoperable, R2 margins, or DM). We still need to define the optimum management.
PO-0766 Is dose de-escalation possible in sarcoma patients treated with extended limb sparing resection?
A. Levy Material and Methods: Data were retrospectively analyzed from 414 consecutive localized limbs STS patients who received irradiation and enlarged surgery at Gustave Roussy from 05/1993 to 05/2012. RT dose level were decided in multidisciplinary staff and depended upon the quality of surgery and margins size.
Results:
The median age was 52 years, the median tumor size was 89 mm, most patients had proximal locations (72%), and G-2-3 tumors (79%). Available histologic analyses after surgery retrieved 84% unifocal tumors and free-tumor margins >1 mm in 69% of cases. Radiotherapy (RT) was delivered prior (13%) or after (87%) surgery. Seven patients (2%) had pre-and a postoperative RT boost. Median delivered RT dose was 50 Gy (36-70 Gy), and 40% received >50Gy. At a median followup of 5.5 years, the 5-year local relapse rates (LRRs) were 7%, 4%, and 13% in the general population, in patients receiving <50Gy and in those who had >50 Gy (p<0.001), respectively. Despite this may due to confounding factors, a dose >50 Gy (HR: 2.6; p= 0.04) remained associated with higher LRRs in the multivariate analysis (MVA), as well as histological subtypes (HR: 3.7; p = 0.002), and surgical margins<1mm (HR: 3.2; p= 0.008). Grade, age, and tumour size were not associated with LRRs in the MVA.
Conclusion:
In this retrospective analysis of patients having enlarged and surgery and RT dose escalation did not allow offsetting local relapse in high-risk patients. This should be evaluated in a larger set of patients all having enlarged surgery. A Prospective study allowing dose refinement in this setting is required. Purpose or Objective: Fluid collection of lymph or blood may accumulate at the site of excision after surgery for soft tissue sarcoma, with reported incidence rates from 10-36%. Though small fluid collections have a high probability of being completely covered within the postoperative radiotherapy (PORT) field, large fluid collections may require a more extensive expansion of CTVs. This study is an unprecedented analysis of fluid collection in relation to radiotherapy outcomes after wide excision of soft tissue sarcoma (STS).
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Material and Methods:
Medical records of 151 patients with STS treated with wide excision followed by adjuvant PORT between 2004 and 2014 were retrospectively reviewed. Only non-recurrent and non-metastatic patients were included. After evaluation of CT and MR images taken at the time of PORT planning, fluid collection was detected in 46 patients (30.5%). Because fluid collection developed more commonly in lower extremity (p<0.001) and higher grade tumors (p= 0.095), only these patients were included in further analyses (n= 76). Fluid collection was present in 35 (46.1%) patients, of which 74.3% and 25.7% had, respectively, either complete or partial coverage in planning target volumes (PTVs) throughout the entire course of PORT.
Results: After a median follow-up of 41 months, patients with and without fluid collection demonstrated local failure rates of 14.3% and 9.8%, and 5-year local control (LC) rates of 83.1% and 86.8%, respectively. The presence of fluid collection had no statistical impact on the clinical outcomes of PORT. Partial coverage of fluid collection showed a low 5year LC rate of 77.8% compared with 85.5% and 86.8% for patients that had complete PTV coverage or absence of fluid collection, respectively, without statistical significance. Post-PORT complications developed in 5 (6.6%) patients, of which 4 had fluid collection. Wound complication developed in 3 (8.6%) of 35 patients with fluid collection and in 1 (2.4%) of 41 patients without fluid collection.
Conclusion:
Fluid collection demonstrated lower LC rates after wide excision and PORT for STS, but with a reasonable wound complication rate of 8.6% when compared with rates of previous studies ranging from 5-17%. Furthermore, partial coverage of fluid collections in PTVs had worse LC rates, thus recommending complete coverage. Future evaluation wth a larger number of cases will be needed for statistical support of our findings. 
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